Pub Date : 2016-06-01DOI: 10.5455/BCP.20151203010237
Z. Ozturk
{"title":"Faces and shadows: cabergoline-induced acute psychosis in a woman with no previous psychiatric history -","authors":"Z. Ozturk","doi":"10.5455/BCP.20151203010237","DOIUrl":"https://doi.org/10.5455/BCP.20151203010237","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88570214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-01DOI: 10.5455/BCP.20150707103818
A. Akpınar, A. Yaman, K. Karakuş, I. Atay, K. Demi̇rci̇
ABSTRACTObjective: In the present study, we aimed to determine the frequency of benzodiazepine prescriptions to patients with psychiatric disorders in Isparta Province, Turkey.Methods: The data was collected retrospectively from records of controlled drugs of Isparta Province in 2011. A total of 11,317 benzodiazepine prescriptions for any kind of psychiatric disorder, written for patients from January 2011 through December 2011 were included. Prescriptions for diagnoses other than psychiatric disorders were excluded.Results: In Isparta Province, one year frequency of benzodiazepine use at least one time was 2.06% (2.58% for females and 1.53% for males). The number for patients aged 65 years or older was found to be 3.92%. Benzodiazepines were prescribed mostly by general practitioners (39.2%), psychiatrists (33.4%), and neurologists (19.2%). The most frequently prescribed benzodiazepines were alprazolam (76.4%), clonazepam (11.4%), and diazepam (6.8%).Conclusion: The frequency of benzodiazepine use in Isp...
{"title":"The Frequency of Benzodiazepine Use in the Isparta Province","authors":"A. Akpınar, A. Yaman, K. Karakuş, I. Atay, K. Demi̇rci̇","doi":"10.5455/BCP.20150707103818","DOIUrl":"https://doi.org/10.5455/BCP.20150707103818","url":null,"abstract":"ABSTRACTObjective: In the present study, we aimed to determine the frequency of benzodiazepine prescriptions to patients with psychiatric disorders in Isparta Province, Turkey.Methods: The data was collected retrospectively from records of controlled drugs of Isparta Province in 2011. A total of 11,317 benzodiazepine prescriptions for any kind of psychiatric disorder, written for patients from January 2011 through December 2011 were included. Prescriptions for diagnoses other than psychiatric disorders were excluded.Results: In Isparta Province, one year frequency of benzodiazepine use at least one time was 2.06% (2.58% for females and 1.53% for males). The number for patients aged 65 years or older was found to be 3.92%. Benzodiazepines were prescribed mostly by general practitioners (39.2%), psychiatrists (33.4%), and neurologists (19.2%). The most frequently prescribed benzodiazepines were alprazolam (76.4%), clonazepam (11.4%), and diazepam (6.8%).Conclusion: The frequency of benzodiazepine use in Isp...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89842627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-01DOI: 10.5455/BCP.20160105112215
Z. Li, Zhenzhen Xiong, Xiehe Liu, Xiangdong Tang, Taomei Li
Kleine-Levin syndrome (KLS) is a rare sleep disorder characterized by various symptoms, such as recurrent episodes of hypersomnia, cognitive abnormalities, psychiatric symptoms, hyperphagia, and behavioral disturbances, and is often confused with other diseases. To date, a number of classic cases of KLS have been identified worldwide; however, incomplete forms of KLS without hyperphagia have rarely been reported. Here, we report a case of a repeatedly hospitalized 24-year-old woman who suffered from psychiatric symptoms, abnormal behaviors, cognitive abnormalities, and recurrent episodes of hypersomnia for eight years. During this period, she was admitted three times, and different diagnoses were considered because the symptoms differed each time. In view of the recurrent episodes of hypersomnia, we monitored the patient using polysomnography (PSG). Carbamazepine and methylphenidate extended-release tablets were used to treat the patient, and beneficial effects were observed. Therefore, when a patient presents with recurrent episodes of hypersomnia, particularly those lasting approximately 20 hours per day, we suggest that psychiatrists should the possibility of KLS.
{"title":"Missing the diagnosis in a young woman with repeated hospital admissions: a case report -","authors":"Z. Li, Zhenzhen Xiong, Xiehe Liu, Xiangdong Tang, Taomei Li","doi":"10.5455/BCP.20160105112215","DOIUrl":"https://doi.org/10.5455/BCP.20160105112215","url":null,"abstract":"Kleine-Levin syndrome (KLS) is a rare sleep disorder characterized by various symptoms, such as recurrent episodes of hypersomnia, cognitive abnormalities, psychiatric symptoms, hyperphagia, and behavioral disturbances, and is often confused with other diseases. To date, a number of classic cases of KLS have been identified worldwide; however, incomplete forms of KLS without hyperphagia have rarely been reported. Here, we report a case of a repeatedly hospitalized 24-year-old woman who suffered from psychiatric symptoms, abnormal behaviors, cognitive abnormalities, and recurrent episodes of hypersomnia for eight years. During this period, she was admitted three times, and different diagnoses were considered because the symptoms differed each time. In view of the recurrent episodes of hypersomnia, we monitored the patient using polysomnography (PSG). Carbamazepine and methylphenidate extended-release tablets were used to treat the patient, and beneficial effects were observed. Therefore, when a patient presents with recurrent episodes of hypersomnia, particularly those lasting approximately 20 hours per day, we suggest that psychiatrists should the possibility of KLS.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76688708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.5455/BCP.20150505104526
C. Tanıdır, I. Tanıdır, K. Bahali, H. Gunes, H. Adaletli, E. Öztürk, Tolga Ünüvar, O. Uneri
ABS TRACT: Insignificant effects of atomoxetine on thyroid functions in children and adolescents with attention deficit and hyperactivity disorder in short term Objective: In this study, we aimed to explore the effects of atomoxetine on thyroid functions in children and adolescents with attention deficit hyperactivity disorder. Methods: A retrospective chart review was done to evaluate the thyroid function tests of patients diagnosed with attention deficit hyperactivity disorder and treated with only atomoxetine. The thyroid function tests of 38 subjects, from both before atomoxetine was started and during an effective dose of atomoxetine treatment, were found from the patient charts and compared statistically. Results: There were no statistically significant differences between the baselines levels of thyroidstimulating hormone (TSH), free T4, and free T3 values and those during an effective dose of atomoxetine treatment. In one subject, four weeks after atomoxetine was started and titrated to the effective dose, an insignificant increase in TSH was observed, which decreased to the normal range after the discontinuation of the atomoxetine treatment. Conclusion: Therapeutic doses of atomoxetine do not seem to change thyroid functions in children and adolescents with attention deficit hyperactivity disorder.
{"title":"Insignificant Effects of Atomoxetine on Thyroid Functions in Children and Adolescents with Attention Deficit and Hyperactivity Disorder in Short Term","authors":"C. Tanıdır, I. Tanıdır, K. Bahali, H. Gunes, H. Adaletli, E. Öztürk, Tolga Ünüvar, O. Uneri","doi":"10.5455/BCP.20150505104526","DOIUrl":"https://doi.org/10.5455/BCP.20150505104526","url":null,"abstract":"ABS TRACT: Insignificant effects of atomoxetine on thyroid functions in children and adolescents with attention deficit and hyperactivity disorder in short term Objective: In this study, we aimed to explore the effects of atomoxetine on thyroid functions in children and adolescents with attention deficit hyperactivity disorder. Methods: A retrospective chart review was done to evaluate the thyroid function tests of patients diagnosed with attention deficit hyperactivity disorder and treated with only atomoxetine. The thyroid function tests of 38 subjects, from both before atomoxetine was started and during an effective dose of atomoxetine treatment, were found from the patient charts and compared statistically. Results: There were no statistically significant differences between the baselines levels of thyroidstimulating hormone (TSH), free T4, and free T3 values and those during an effective dose of atomoxetine treatment. In one subject, four weeks after atomoxetine was started and titrated to the effective dose, an insignificant increase in TSH was observed, which decreased to the normal range after the discontinuation of the atomoxetine treatment. Conclusion: Therapeutic doses of atomoxetine do not seem to change thyroid functions in children and adolescents with attention deficit hyperactivity disorder.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78141022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.5455/BCP.20151013010546
H. Gunes, C. Tanıdır, H. Adaletli, O. Uneri
Pica is defined as persistent eating of substances that have no nutritive value for at least one month in a developmentally inappropriate manner and the behavior should not be part of a culturally appropriate action. Although the etiological factors have not been clearly described, several psychiatric conditions including mental retardation, developmental disorders, dementia, schizophrenia, autism spectrum disorder, major depressive disorder, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD) have been reported in association with pica 1-3 . In this report, we present a
{"title":"Effect of Methylphenidate on Impulsivity in a Child with Pica and Attention Deficit Hyperactivity Disorder","authors":"H. Gunes, C. Tanıdır, H. Adaletli, O. Uneri","doi":"10.5455/BCP.20151013010546","DOIUrl":"https://doi.org/10.5455/BCP.20151013010546","url":null,"abstract":"Pica is defined as persistent eating of substances that have no nutritive value for at least one month in a developmentally inappropriate manner and the behavior should not be part of a culturally appropriate action. Although the etiological factors have not been clearly described, several psychiatric conditions including mental retardation, developmental disorders, dementia, schizophrenia, autism spectrum disorder, major depressive disorder, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD) have been reported in association with pica 1-3 . In this report, we present a","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77125219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.5455/BCP.20151019014403
A. Trevizol, I. Sato, Q. Cordeiro, P. Shiozawa
Polydipsia is characterized by excessive water drinking. It has been related to psychiatric conditions such as schizophrenia, cognitive impairments, and neurological disorders such as brain tumors. Excessive drinking may lead to hyponatremia, nausea, vomiting, delirium, ataxia, seizures, coma, and even death. Here, we present a case of polydipsia secondary to quetiapine use in a patient with schizophrenia. JVO, 20 years old, male, single, diagnosed with schizophrenia according to the DSM-IV criteria for about six years ago. The patient was under pharmacological treatment with quetiapine in increasing doses, reaching 800 mg/day. One week later, he presented at the psychiatric emergency room with nausea, vomiting, confusion, and disorientation. Psychiatric symptoms included blunt affect, auditory hallucinations (voices commenting on patient’s actions and conversing with one another), and persecutory delusions. In fact, the patient was persecutory with near relatives and daily activit ies were l imited by his psychotic behaviors. Increased water intake was observed and diuresis reached approximately 12 liters/ day. Complementary tests showed hyponatrenia with a serum sodium level of 105 mmol/L (135145 mmol/L). All other laboratory tests and neuroimaging studies were within normal range. Other possible etiologies of polydipsia, such as diabetes mellitus, diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and thyroid or adrenal dysfunctions were excluded. Psychogenic polydipsia was a possible differential diagnosis, however we could observe a strong temporal association between polydipsia symptoms intensity and quetiapine u s e . F u r t h e r m o r e , w i t h q u e t i a p i n e discontinuation, clinical remission of polydipsia symptoms with normalization of complementary laboratory tests were obtained. The patient has never manifested such behavior before quetiapine use. Initial treatment was 1,000 ml intravenous infusion of sodium chloride 0.9% and water intake restriction to one liter per 24 hours. Quetiapine was replaced by risperidone. Patient showed improvement with normalization of serum sodium levels and presented with clinical improvement during the next three days. In polydipsia the excessive drinking of water reduces plasma osmolarity. Considering the use of antipsychotic drugs inducing polydipsia, it has been previously hypothesized that the use of neuroleptics may increase vasopressin (ADH) secretion, therefore inducing water retention. Another theoretical mechanism could be based on possible anticolinergic effects inherent to antipsychotics that would induce sensation of thirst. Regarding the specific use of quetiapine, there has been only one case in medical literature reporting quetiapine inducing hyponatremia. However, the metabolic imbalance was due to syndrome of inappropriate secretion of antidiuretic hormone rather than secondary to polydipsia. In this present case, we report and highlight DOI:
{"title":"Polydipsia Secondary to Quetiapine Use: A Case Report","authors":"A. Trevizol, I. Sato, Q. Cordeiro, P. Shiozawa","doi":"10.5455/BCP.20151019014403","DOIUrl":"https://doi.org/10.5455/BCP.20151019014403","url":null,"abstract":"Polydipsia is characterized by excessive water drinking. It has been related to psychiatric conditions such as schizophrenia, cognitive impairments, and neurological disorders such as brain tumors. Excessive drinking may lead to hyponatremia, nausea, vomiting, delirium, ataxia, seizures, coma, and even death. Here, we present a case of polydipsia secondary to quetiapine use in a patient with schizophrenia. JVO, 20 years old, male, single, diagnosed with schizophrenia according to the DSM-IV criteria for about six years ago. The patient was under pharmacological treatment with quetiapine in increasing doses, reaching 800 mg/day. One week later, he presented at the psychiatric emergency room with nausea, vomiting, confusion, and disorientation. Psychiatric symptoms included blunt affect, auditory hallucinations (voices commenting on patient’s actions and conversing with one another), and persecutory delusions. In fact, the patient was persecutory with near relatives and daily activit ies were l imited by his psychotic behaviors. Increased water intake was observed and diuresis reached approximately 12 liters/ day. Complementary tests showed hyponatrenia with a serum sodium level of 105 mmol/L (135145 mmol/L). All other laboratory tests and neuroimaging studies were within normal range. Other possible etiologies of polydipsia, such as diabetes mellitus, diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and thyroid or adrenal dysfunctions were excluded. Psychogenic polydipsia was a possible differential diagnosis, however we could observe a strong temporal association between polydipsia symptoms intensity and quetiapine u s e . F u r t h e r m o r e , w i t h q u e t i a p i n e discontinuation, clinical remission of polydipsia symptoms with normalization of complementary laboratory tests were obtained. The patient has never manifested such behavior before quetiapine use. Initial treatment was 1,000 ml intravenous infusion of sodium chloride 0.9% and water intake restriction to one liter per 24 hours. Quetiapine was replaced by risperidone. Patient showed improvement with normalization of serum sodium levels and presented with clinical improvement during the next three days. In polydipsia the excessive drinking of water reduces plasma osmolarity. Considering the use of antipsychotic drugs inducing polydipsia, it has been previously hypothesized that the use of neuroleptics may increase vasopressin (ADH) secretion, therefore inducing water retention. Another theoretical mechanism could be based on possible anticolinergic effects inherent to antipsychotics that would induce sensation of thirst. Regarding the specific use of quetiapine, there has been only one case in medical literature reporting quetiapine inducing hyponatremia. However, the metabolic imbalance was due to syndrome of inappropriate secretion of antidiuretic hormone rather than secondary to polydipsia. In this present case, we report and highlight DOI:","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82728321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.5455/BCP.20150629110950
E. Karslioğlu, E. Özalp, İsmail Volkan Şahi̇ner, M. Ozturk, Melike Nur Albayrak, Serap Aydin, Sadik Aydin, O. Yuncu, A. Çayköylü
Objective: Combined antipsychotic treatment is frequently used in clinical practice either to improve the symptom control or to reduce the severity of side effects. The expected benefits by combining different antipsychotics include active cross-titration and co-utilization of different administration routes of the therapeutic agents. However, except the add-on therapies to clozapine, there is no objective evidence implying the superiority of combined therapy over monotherapy. Furthermore, there are a number of published case reports of significant side effects accompanying combined antipsychotic usage such as extrapyramidal and metabolic symptoms, seizures, and electrocardiographic abnormalities. It is also argued that switching into a new therapeutic agent might be more beneficial than augmenting the ongoing medication by polypharmacy. Here, we studied on a group of hospitalized schizophrenia patients in a training and research hospital in Turkey whether the Positive and Negative Symptom Scale (PANSS) scores differ between the patients under monotherapy and combined therapy. Methods: Hospital records belonging patients with schizophrenia who were followed up between the years of 2003 and 2013 were retrieved. Schizophrenia diagnoses were re-evaluated and confirmed according to the DSM-IV-TR criteria. All the patients who met the diagnostic criteria and having PANSS subscale scores (n=158) were included in the study. PANSS scores at the time of hospitalization are represented by adding “-before” suffixes, while the ones at the time of discharge by adding “-after”. Results: Our series composed of 158 schizophrenia patients (54 women and 104 men). When the medications were reviewed, we found that 66 patients (41.8%) were treated with a single drug and the atypical antipsychotics were the most commonly used group. Multiple drugs were combined on 92 patients (58.2%) and the most common combination was the “atypical + typical” antipsychotics. PANSS subscales and their comparisons among the groups of monotherapy and combined therapy revealed a slight statistical difference in PANSS negative scores at the time of hospitalization, although we found no significant changes in terms of PANSS scales, in general. Conclusion: In this study, we presented the overall frequency and patterns of our combined antipsychotic therapy in our daily routine work. We only used severity of symptoms in our study, and observed no differences between mono and combined therapy groups in terms of the PANSS evaluation. Further clinical studies with clinical, metabolic, and laboratory data as well as the long follow-ups are needed to uncover if combined therapy proves to be beneficial over monotherapy.
{"title":"Does Combined Antipsychotic Treatment Provide Better Control on Symptoms in Patients with Schizophrenia than the Monotherapy","authors":"E. Karslioğlu, E. Özalp, İsmail Volkan Şahi̇ner, M. Ozturk, Melike Nur Albayrak, Serap Aydin, Sadik Aydin, O. Yuncu, A. Çayköylü","doi":"10.5455/BCP.20150629110950","DOIUrl":"https://doi.org/10.5455/BCP.20150629110950","url":null,"abstract":"Objective: Combined antipsychotic treatment is frequently used in clinical practice either to improve the symptom control or to reduce the severity of side effects. The expected benefits by combining different antipsychotics include active cross-titration and co-utilization of different administration routes of the therapeutic agents. However, except the add-on therapies to clozapine, there is no objective evidence implying the superiority of combined therapy over monotherapy. Furthermore, there are a number of published case reports of significant side effects accompanying combined antipsychotic usage such as extrapyramidal and metabolic symptoms, seizures, and electrocardiographic abnormalities. It is also argued that switching into a new therapeutic agent might be more beneficial than augmenting the ongoing medication by polypharmacy. Here, we studied on a group of hospitalized schizophrenia patients in a training and research hospital in Turkey whether the Positive and Negative Symptom Scale (PANSS) scores differ between the patients under monotherapy and combined therapy. \u0000Methods: Hospital records belonging patients with schizophrenia who were followed up between the years of 2003 and 2013 were retrieved. Schizophrenia diagnoses were re-evaluated and confirmed according to the DSM-IV-TR criteria. All the patients who met the diagnostic criteria and having PANSS subscale scores (n=158) were included in the study. PANSS scores at the time of hospitalization are represented by adding “-before” suffixes, while the ones at the time of discharge by adding “-after”. \u0000Results: Our series composed of 158 schizophrenia patients (54 women and 104 men). When the medications were reviewed, we found that 66 patients (41.8%) were treated with a single drug and the atypical antipsychotics were the most commonly used group. Multiple drugs were combined on 92 patients (58.2%) and the most common combination was the “atypical + typical” antipsychotics. PANSS subscales and their comparisons among the groups of monotherapy and combined therapy revealed a slight statistical difference in PANSS negative scores at the time of hospitalization, although we found no significant changes in terms of PANSS scales, in general. \u0000Conclusion: In this study, we presented the overall frequency and patterns of our combined antipsychotic therapy in our daily routine work. We only used severity of symptoms in our study, and observed no differences between mono and combined therapy groups in terms of the PANSS evaluation. Further clinical studies with clinical, metabolic, and laboratory data as well as the long follow-ups are needed to uncover if combined therapy proves to be beneficial over monotherapy.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87235185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.5455/BCP.20150714054535
H. Kocakaya, Z. Çelikbaş, M. Yıldız, E. Songur, S. Batmaz
{"title":"Ziprasidone use Associated with Sexual Hyperarousal","authors":"H. Kocakaya, Z. Çelikbaş, M. Yıldız, E. Songur, S. Batmaz","doi":"10.5455/BCP.20150714054535","DOIUrl":"https://doi.org/10.5455/BCP.20150714054535","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72639308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.5455/BCP.20150703013708
E. Tasgin, O. Oner, P. Yurtbaşı, K. Munir
OBJECTIVE To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting. METHODS The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month. Treatment response was defined as larger than 25% or more decrease in pre-treatment the Conners Parent Rating Scale (CPRS) or the Conners Teacher Rating Scale (CTRS) total scores and the Clinical Global Impression improvement with drug treatment 3 (minimally improved) or higher. Maternal ADHD, antisocial behavior and anxiety/depression ratings were obtained by the Adult Self Rating (ASR). Logistic regression analyses were computed in order to calculate the effects of gender; age; ADHD subtype; comorbid anxiety disorder, learning disorder, oppositional defiant/conduct disorder; maternal ASR Anxiety/Depression, ADHD and Antisocial scores. RESULTS 35.2% of subjects had statistically significant 25% or more decrease in pretreatment CPRS total scores and 38.6% of subjects had statistically significant 25% or more decrease in pretreatment CTRS total scores. The subjects with comorbid anxiety disorder had the poorest drug response. Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p<0.01; OR=0.95, 95% CI: 0.9-0.99, p<0.05) and CTRS total scores (OR=0.9, 95% CI: 0.82-0.99, OR=0.95, 95% CI: 0.91-1, p<0.05). Baseline rating scores were also important predictors of drug treatment response. Effects of age, gender and maternal ADHD were not statistically significant. CONCLUSION ADHD children and adolescents with comorbid anxiety disorders and those whose mothers have more self-reports of antisocial and depressive symptoms showed less favorable short-term response to OROS-MPH. These subjects may require further attention and additional interventions to augment treatment with OROS methylphenidate.
{"title":"Effects of maternal symptom ratings and other clinical features on short-term treatment response to OROS methylphenidate in children and adolescents with ADHD in a naturalistic clinical setting.","authors":"E. Tasgin, O. Oner, P. Yurtbaşı, K. Munir","doi":"10.5455/BCP.20150703013708","DOIUrl":"https://doi.org/10.5455/BCP.20150703013708","url":null,"abstract":"OBJECTIVE To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting. METHODS The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month. Treatment response was defined as larger than 25% or more decrease in pre-treatment the Conners Parent Rating Scale (CPRS) or the Conners Teacher Rating Scale (CTRS) total scores and the Clinical Global Impression improvement with drug treatment 3 (minimally improved) or higher. Maternal ADHD, antisocial behavior and anxiety/depression ratings were obtained by the Adult Self Rating (ASR). Logistic regression analyses were computed in order to calculate the effects of gender; age; ADHD subtype; comorbid anxiety disorder, learning disorder, oppositional defiant/conduct disorder; maternal ASR Anxiety/Depression, ADHD and Antisocial scores. RESULTS 35.2% of subjects had statistically significant 25% or more decrease in pretreatment CPRS total scores and 38.6% of subjects had statistically significant 25% or more decrease in pretreatment CTRS total scores. The subjects with comorbid anxiety disorder had the poorest drug response. Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p<0.01; OR=0.95, 95% CI: 0.9-0.99, p<0.05) and CTRS total scores (OR=0.9, 95% CI: 0.82-0.99, OR=0.95, 95% CI: 0.91-1, p<0.05). Baseline rating scores were also important predictors of drug treatment response. Effects of age, gender and maternal ADHD were not statistically significant. CONCLUSION ADHD children and adolescents with comorbid anxiety disorders and those whose mothers have more self-reports of antisocial and depressive symptoms showed less favorable short-term response to OROS-MPH. These subjects may require further attention and additional interventions to augment treatment with OROS methylphenidate.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85584091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.5455/BCP.20161123044657
F. Aricioglu, C. Ozkartal, G. Unal, S. Dursun, M. Cetin, N. Müller
Schizophrenia is a serious mental illness that affects approximately 1% of the population worldwide, with positive, negative and cognitive dysfunctions and a significant deterioration in psychosoci...
{"title":"Neuroinflammation in Schizophrenia: A Critical Review and The Future","authors":"F. Aricioglu, C. Ozkartal, G. Unal, S. Dursun, M. Cetin, N. Müller","doi":"10.5455/BCP.20161123044657","DOIUrl":"https://doi.org/10.5455/BCP.20161123044657","url":null,"abstract":"Schizophrenia is a serious mental illness that affects approximately 1% of the population worldwide, with positive, negative and cognitive dysfunctions and a significant deterioration in psychosoci...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82259518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：